Learn how Prospection analysed real-world data and identified a shift towards newer novel agents for chronic lymphocytic leukemia (CLL) treatment, providing insights to support their client's launch planning, submission modelling and market preparations for their new treatment. Prospection analysed treatment...

This study analysed the utilization of ibrutinib, a BTK inhibitor, in treating chronic lymphocytic leukemia in Australia. It compared real-world data from the Pharmaceutical Benefits Scheme (PBS) to the RESONATE clinical trial, providing insights into ibrutinib use in the general...